Antıbıotıc sensıtıvıty profıle of Klebsıella Pneumonıae straıns ısolated from COVID-19 patıents, usıng the Vıtek 2 system
Abstract
Purpose of the study. Analysis of the sensitivity of Klebsiella pneumoniae strains isolated from patients with COVID-19 to various groups of antibiotics using the VITEK 2 system.
Material and research methods. In this study, the sensitivity of Klebsiella pneumoniae strains isolated from patients with COVID-19 to various groups of antibiotics was assessed using the automated VITEK 2 system. Of the 210 patients, 14.4% of Klebsiella pneumoniae strains were isolated. The highest sensitivity was recorded to aminoglycosides and carbapenems: Amikacin (100%), Fosfomycin (100%), Imipenem (88%), Levofloxacin (85.19%). The strains showed the greatest resistance to Ampicillin, Cefazolin and Ampicillin / Sulbactam (89-100%). The overall mean susceptibility rate was 54.2%.
Results of the study and discussion. The results demonstrate a high level of resistance of Klebsiella pneumoniae to many groups of antibiotics, while certain drugs retain high efficacy. This emphasizes the need to select empirical therapy based on local resistance data.
Conclusion. Klebsiella pneumoniae isolated from patients are resistant to ampicillin and ampicillin/sulbactam antibiotics and cefazolin and ceftriaxone drugs. Carbapenems, especially imipenem and meropenem, are still highly effective and are important as a drug of choice in severe cases. 100% susceptibility of the microorganism to amikacin was revealed.
About the Authors
S. T. Zhumamurodov
Tashkent Medical Academy
Uzbekistan
Uzbekistan
Zhumamurodov S.T. - Assistant of the Department of Microbiology
Tashkent
Z. A. Nuruzova
Tashkent Medical Academy
Uzbekistan
Uzbekistan
Nuruzova Z.A.
Tashkent
References
1. Всемирная организация здравоохранения. Устойчивость к противомикробным препаратам: глобальный доклад по эпиднадзору за 2014 г. Женева: ВОЗ; 2014 год.
2. Роусон Т.М., Мур Л.С. Кастро-Санчес Э., и др. COVID-19 и потенциальное долгосрочное влияние на устойчивость к противомикробным препаратам. J Противомикробная химиотерапия. 2020; 75(7):1681–1684.
3. Ventola CL. Кризис антибиотикорезистентности: часть 1: причины и угрозы. Т. 2015; 40(4):277–283.
4. CLSI. Стандарты эффективности для тестирования чувствительности к противомикробным препаратам. 33-е изд., CLSI Supplement M100. Уэйн, Пенсильвания: Институт клинических и лабораторных стандартов; 2023 год.
5. Такконелли Э., Каррара Э., Савольди А. и др. Открытие, научные исследования и разработка новых антибиотиков: список приоритетных для ВОЗ бактерий, устойчивых к антибиотикам. Ланцет Инфект Дис. 2018; 18(3):318–327.
6. Фатторини Л., Крети Р., Пальма С., Пантости А. Устойчивость к антибиотикам среди пациентов с COVID-19: систематический обзор. Клин Микробиол Инфект. 2021; 27(1):35–41.
7. Lemenand O, Coeffic T, Thibaut S, et al. Распространенность ESBL-продуцирующих энтеробактерий у пациентов с COVID-19. J. Hosp Infect. 2021; 112:91–94.
Review
For citations:
Zhumamurodov S.T., Nuruzova Z.A. Antıbıotıc sensıtıvıty profıle of Klebsıella Pneumonıae straıns ısolated from COVID-19 patıents, usıng the Vıtek 2 system. Herald of the medical and social institute of Tajikistan. 2025;(2):12-21. (In Russ.)
Views:
119
Email this article 